Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.13
+3.4%
$4.49
$3.42
$7.62
$288.38M1.941.57 million shs1.73 million shs
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$3.61
+0.8%
$3.56
$1.75
$10.00
$246.09M0.67720,717 shs1.04 million shs
Immutep Limited stock logo
IMMP
Immutep
$2.03
+2.5%
$1.72
$1.32
$3.34
$296.46M1.8222,212 shs104,484 shs
InterCure Ltd. stock logo
INCR
InterCure
$1.54
+2.0%
$1.45
$1.17
$3.39
$70.18M1.2529,252 shs9,418 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.00%+5.99%+15.54%-18.70%-27.95%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
0.00%-18.51%+11.42%-26.02%+62.61%
Immutep Limited stock logo
IMMP
Immutep
0.00%+9.73%+31.82%+3.57%-28.01%
InterCure Ltd. stock logo
INCR
InterCure
0.00%-3.14%+12.00%-4.94%-53.05%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.3236 of 5 stars
0.02.00.00.01.60.80.6
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
2.5787 of 5 stars
3.61.00.00.03.32.50.6
Immutep Limited stock logo
IMMP
Immutep
1.5827 of 5 stars
3.52.00.00.02.80.00.0
InterCure Ltd. stock logo
INCR
InterCure
1.0189 of 5 stars
0.05.00.00.02.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3.25
Buy$16.33352.45% Upside
Immutep Limited stock logo
IMMP
Immutep
3.00
Buy$7.00244.83% Upside
InterCure Ltd. stock logo
INCR
InterCure
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INCR, CRVS, ACB, and IMMP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$15.00 ➝ $17.00
3/26/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$14.00 ➝ $15.00
3/26/2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.90$0.19 per share26.35$8.18 per share0.63
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/A$0.79 per shareN/A
Immutep Limited stock logo
IMMP
Immutep
$5.14M57.68N/AN/A$1.05 per share1.93
InterCure Ltd. stock logo
INCR
InterCure
$238.85M0.29N/AN/A$2.72 per share0.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.05102.6211.66N/A0.42%0.59%0.42%6/19/2025 (Estimated)
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$27.03M-$0.98N/AN/AN/AN/A-70.71%-45.90%8/5/2025 (Estimated)
Immutep Limited stock logo
IMMP
Immutep
-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
InterCure Ltd. stock logo
INCR
InterCure
-$16.83MN/A0.00N/AN/AN/AN/AN/A

Latest INCR, CRVS, ACB, and IMMP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.13-$0.13N/A-$0.13N/AN/A
3/25/2025Q4 2024
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.12-$0.18-$0.06-$0.18N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
Immutep Limited stock logo
IMMP
Immutep
N/AN/AN/AN/AN/A
InterCure Ltd. stock logo
INCR
InterCure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
0.92
0.92
Immutep Limited stock logo
IMMP
Immutep
0.01
18.25
18.25
InterCure Ltd. stock logo
INCR
InterCure
0.15
1.78
1.15

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
Immutep Limited stock logo
IMMP
Immutep
2.32%
InterCure Ltd. stock logo
INCR
InterCure
8.34%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
28.50%
Immutep Limited stock logo
IMMP
Immutep
3.07%
InterCure Ltd. stock logo
INCR
InterCure
0.24%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3068.17 million44.15 millionOptionable
Immutep Limited stock logo
IMMP
Immutep
2,021146.04 million141.09 millionOptionable
InterCure Ltd. stock logo
INCR
InterCure
35045.57 million45.46 millionOptionable

Recent News About These Companies

InterCure names Alexander Rabinovich as Chairman, replacing Ehud Barak
InterCure Secures Major Funding to Boost Growth
Rising High: Exclusive talk with house of brands Carma HoldCo
InterCure Ltd. (INCR)
Electreon Wireless Ltd (ELWS)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$5.13 +0.17 (+3.43%)
Closing price 05/16/2025 04:00 PM Eastern
Extended Trading
$5.07 -0.06 (-1.17%)
As of 05/16/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$3.61 +0.03 (+0.84%)
Closing price 05/16/2025 04:00 PM Eastern
Extended Trading
$3.54 -0.07 (-2.05%)
As of 05/16/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Immutep stock logo

Immutep NASDAQ:IMMP

$2.03 +0.05 (+2.53%)
Closing price 05/16/2025 04:00 PM Eastern
Extended Trading
$2.05 +0.02 (+0.99%)
As of 05/16/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

InterCure stock logo

InterCure NASDAQ:INCR

$1.54 +0.03 (+1.99%)
Closing price 05/16/2025 03:54 PM Eastern
Extended Trading
$1.51 -0.03 (-1.95%)
As of 05/16/2025 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.